Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPO | P22079 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407748 | 0.87 | LPO (0.44) | LPOLMNACYP1A2ALDH1A1POLB | |
| SCHEMBL28785277 | 0.85 | BCHE (0.43) | LMNACYP1A2ALDH1A1POLBKMT2A | |
| SCHEMBL729229 | 0.84 | AGTR1 (0.40) | LMNAALDH1A1POLBKMT2ATLR7 | |
| SCHEMBL18686228 | 0.84 | AGTR1 (0.40) | LMNAALDH1A1POLBKMT2ATLR7 | |
| SCHEMBL9880599 | 0.84 | CETP (0.44) | PPARGPPARAALDH1A1POLBAGTR1 | |
| SCHEMBL28236700 | 0.83 | TLR7 (0.40) | LMNAALDH1A1POLBKMT2APLA2G4A | |
| SCHEMBL10516104 | 0.79 | TSHR (0.43) | LMNACYP1A2ALDH1A1NPSR1 | |
| SCHEMBL27478632 | 0.78 | AGTR1 (0.38) | PPARGPPARAPLA2G4ATLR7AGTR1 | |
| SCHEMBL27690028 | 0.78 | AGTR1 (0.41) | LMNACYP1A2ALDH1A1POLBKMT2A | |
| SCHEMBL1978411 | 0.78 | AGTR1 (0.44) | LMNACYP1A2ALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969577-B2 | Curable composition comprising a thermolatent base | BASF SE (DE) | 2015-03-03 | — | — | US | disclosed |
| US-20110245375-A1 | CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE | BASF SE (DE) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245375-A1 | CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE | COIL, MAPT, ASH2L | LPO 1711/4885LMNA 1354/4885CYP1A2 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.